usbiostock2018-06-25 23:04
$Merrimack Pharmaceuticals, Inc. (MACK)$ 公司公布 istiratumab (MM-141)治疗转移性胰腺癌临床2期试验一线数据,该试验未能满足主要和次要终点,公司将终止MM-141的开发。公司的另外两个药物MM-121和MM-310预计在2018年下半年公布数据。查看全文
会跑的猪2017-09-02 00:29
回复@淘沙见金: 这个走势想起来 $Merrimack Pharmaceuticals, Inc.(MACK)$ ,把自己唯一approved的药卖了,然后干了一件巨SB的事,把卖的钱做了一个特殊的分红。公司剩余的pipeline全部都处于早期,然后股价就不回头的往下掉//@淘沙见金:回复@会跑的猪:Profit taking and shorts in play. Need to ...查看全文
智通财经APP获悉,周三,美国生物技术公司Merrimack Pharma(MACK.US)的法国癌症治疗合作伙伴Ipsen S.A.宣布,其药物Onivyde作为一种组合疗法,在一种胰腺癌的后期试验中达到了主要终点。截至发稿,Merrimack Pharma盘前涨238.75%,报13.... 网页链接
$Merrimack(MACK)$ 15-12G Securities registration termination [Section 12(g)] Accession Number: 0001193125-24-142837 Act: 34 Size: 11 KB 网页链接
$Merrimack(MACK)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-060478 Act: 34 Size: 3 MB 网页链接
$Merrimack(MACK)$ 25 Notification of the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001193125-24-136243 Act: 34 Size: 12 KB 网页链接
$Merrimack(MACK)$ 8-K Current report, items 5.07, 7.01, and 9.01 Accession Number: 0001193125-24-136237 Act: 34 Size: 189 KB 网页链接
$Merrimack(MACK)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-24-134775 Act: 34 Size: 56 KB 网页链接
$Merrimack(MACK)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001193125-24-134773 Act: 34 Size: 197 KB 网页链接
$Merrimack(MACK)$ 8-K Current report, items 3.01, 7.01, and 9.01 Accession Number: 0001193125-24-125367 Act: 34 Size: 201 KB 网页链接
$Merrimack(MACK)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-24-125372 Act: 34 Size: 59 KB 网页链接
$Merrimack(MACK)$ DEFR14A Revised definitive proxy soliciting materials Accession Number: 0001193125-24-083441 Act: 34 Size: 619 KB 网页链接
$Merrimack制药(MACK)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001193125-24-078910 Act: 34 Size: 194 KB 网页链接